Janux Therapeutics JANX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.73M— | $0— | $10M+2,178% | $0-100% | $0-100% | ||
| $26.81M+7.0% | $31.55M+51.6% | $34.63M+86.0% | $34.66M+133% | $25.06M+78.1% | ||
| $11.13M+13.1% | $10.85M+32.1% | $10.62M-39.9% | $10.45M+33.7% | $9.84M+34.0% | ||
| $37.95M+8.7% | $42.4M+46.1% | $45.25M+24.7% | $45.12M+98.6% | $34.9M+63.0% | ||
| -$34.21M+2.0% | -$42.4M-46.1% | -$35.25M+1.6% | -$45.12M-226% | -$34.9M-73.1% | ||
| -916.5%— | —— | -352.5%+7,812pp | —— | —— | ||
| $9.85M-13.5% | $10.46M+18.7% | $10.94M+40.5% | $11.26M+43.2% | $11.39M+111% | ||
| $9.85M-13.5% | $10.46M+18.7% | $10.94M+40.5% | $11.26M+43.2% | $11.39M+111% | ||
| -$24.36M-3.6% | -$31.95M-58.0% | -$24.31M+13.4% | -$33.86M-468% | -$23.51M-59.3% | ||
| -652.6%— | —— | -243.1%+6,148pp | —— | —— | ||
| -$0.39-2.6% | -$0.51-45.7% | -$0.39+23.5% | -$0.55-400% | -$0.38-26.7% | ||
| -$0.39-2.6% | -$0.51-45.7% | -$0.39+23.5% | -$0.55-400% | -$0.38-26.7% | ||
| 62.7M+1.4% | 62M+15.3% | 62M+13.5% | 61.9M+13.7% | 61.8M+26.0% | ||
| 62.7M+1.4% | 62M+15.3% | 62M+13.5% | 61.9M+13.7% | 61.8M+26.0% | ||
| $9.85M-13.5% | $10.46M+18.7% | $10.94M+40.5% | $11.26M+43.2% | $11.39M+111% | ||
| -$34.21M+2.0% | -$42.4M-46.1% | -$35.25M+1.6% | -$45.12M-226% | -$34.9M-73.1% | ||
| -$33.74M+1.8% | -$41.93M-47.1% | -$34.75M+1.6% | -$44.58M-235% | -$34.38M-75.1% | ||
| -$33.74M+1.8% | -$41.93M-47.1% | -$34.75M+1.6% | -$44.58M-235% | -$34.38M-75.1% | ||
| -903.9%— | —— | -347.5%+7,701pp | —— | —— | ||
| -$34.21M+2.0% | -$42.4M-46.1% | -$35.25M+1.6% | -$45.12M-226% | -$34.9M-73.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Janux Therapeutics's revenue?
- Janux Therapeutics (JANX) generated $13.7M in revenue over the trailing twelve months, up 47.1% year over year.
- Is Janux Therapeutics profitable?
- Janux Therapeutics is not currently profitable: it reported a net loss of $114.5M over the trailing twelve months, a -833.6% net margin.
- What is Janux Therapeutics's earnings per share?
- Janux Therapeutics's diluted EPS over the trailing twelve months is $-1.84.
- Where does Janux Therapeutics's income statement data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
